Francois Brisebois
Stock Analyst at Oppenheimer
(2.35)
# 2,553
Out of 5,127 analysts
85
Total ratings
41.38%
Success rate
0.85%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $6.23 | +28.41% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $5.77 | +3.99% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $11.22 | +613.01% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $5.22 | +206.51% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $1.78 | +124.72% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $78.08 | -7.79% | 7 | Jan 22, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $37.55 | +62.45% | 6 | Jan 13, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $14.03 | +42.55% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $10.75 | +160.47% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $21.50 | +39.53% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $143 → $163 | $292.63 | -44.30% | 4 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $19.39 | +183.65% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.67 | +2,155.64% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $8.49 | -29.33% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $5.20 | +111.54% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $22.69 | -38.30% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $18.99 | +242.29% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $4.16 | +140.38% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $19.37 | +85.85% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $2,500 → $1,500 | $3.44 | +43,568.12% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.60 | +337,400.00% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $3.30 | +233.33% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $3.34 | +438.92% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $7.82 | +539.39% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $0.83 | +388,249.51% | 1 | Feb 4, 2020 |
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $6.23
Upside: +28.41%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $5.77
Upside: +3.99%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $11.22
Upside: +613.01%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $5.22
Upside: +206.51%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $1.78
Upside: +124.72%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $78.08
Upside: -7.79%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $37.55
Upside: +62.45%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $14.03
Upside: +42.55%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $10.75
Upside: +160.47%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $21.50
Upside: +39.53%
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $292.63
Upside: -44.30%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $19.39
Upside: +183.65%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.67
Upside: +2,155.64%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $8.49
Upside: -29.33%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $5.20
Upside: +111.54%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $22.69
Upside: -38.30%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $18.99
Upside: +242.29%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $4.16
Upside: +140.38%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $19.37
Upside: +85.85%
Apr 3, 2023
Maintains: Outperform
Price Target: $2,500 → $1,500
Current: $3.44
Upside: +43,568.12%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.60
Upside: +337,400.00%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $3.30
Upside: +233.33%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $3.34
Upside: +438.92%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $7.82
Upside: +539.39%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $0.83
Upside: +388,249.51%